343 related articles for article (PubMed ID: 37012686)
1. Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Are Associated With Reduced Risk of SARS-CoV-2 Infection Without Comorbidities Including Diabetes, Hypertension, and Dyslipidemia: A Propensity Score-Matched Nationwide Cohort Study.
Kim B; Jung JH; Han K; Kang S; Lee E; Chung H; Kim SG; Cho SJ
J Korean Med Sci; 2023 Apr; 38(13):e99. PubMed ID: 37012686
[TBL] [Abstract][Full Text] [Related]
2. Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study.
Park J; You SC; Cho J; Park CH; Shin WG; Park RW; In Seo S
BMC Pharmacol Toxicol; 2022 Jan; 23(1):9. PubMed ID: 35039078
[TBL] [Abstract][Full Text] [Related]
3. Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.
Shin GY; Park JM; Hong J; Cho YK; Yim HW; Choi MG
Am J Gastroenterol; 2021 Jun; 116(6):1211-1219. PubMed ID: 34074826
[TBL] [Abstract][Full Text] [Related]
4. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching.
Lee SW; Ha EK; Yeniova AÖ; Moon SY; Kim SY; Koh HY; Yang JM; Jeong SJ; Moon SJ; Cho JY; Yoo IK; Yon DK
Gut; 2021 Jan; 70(1):76-84. PubMed ID: 32732368
[TBL] [Abstract][Full Text] [Related]
5. Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis.
Israelsen SB; Ernst MT; Lundh A; Lundbo LF; Sandholdt H; Hallas J; Benfield T
Clin Gastroenterol Hepatol; 2021 Sep; 19(9):1845-1854.e6. PubMed ID: 33989790
[TBL] [Abstract][Full Text] [Related]
6. Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study.
Kieboom BC; Kiefte-de Jong JC; Eijgelsheim M; Franco OH; Kuipers EJ; Hofman A; Zietse R; Stricker BH; Hoorn EJ
Am J Kidney Dis; 2015 Nov; 66(5):775-82. PubMed ID: 26123862
[TBL] [Abstract][Full Text] [Related]
7. Long-term continuous use of proton-pump inhibitors is associated with renal function decline in patients without acute kidney injury.
Hatakeyama Y; Horino T; Matsumoto T; Terada Y; Okuhara Y
Clin Exp Nephrol; 2021 Oct; 25(10):1087-1092. PubMed ID: 34089392
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.
Park JH; Song YM; Jung JH; Han K
Bone; 2020 Jun; 135():115306. PubMed ID: 32126312
[TBL] [Abstract][Full Text] [Related]
9. Proton pump inhibitors and chronic kidney disease risk: a comparative study with histamine-2 receptor antagonists.
Kweon T; Kim Y; Lee KJ; Seo WW; Seo SI; Shin WG; Shin DH
Sci Rep; 2023 Dec; 13(1):21169. PubMed ID: 38036592
[TBL] [Abstract][Full Text] [Related]
10. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
[TBL] [Abstract][Full Text] [Related]
11. Beyond uncertainty: Negative findings for the association between the use of proton pump inhibitors and risk of dementia.
Park SK; Nam JH; Lee H; Chung H; Lee EK; Shin JY
J Gastroenterol Hepatol; 2019 Dec; 34(12):2135-2143. PubMed ID: 31145825
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of children and adolescents first prescribed proton pump inhibitors or histamine-2-receptor antagonists: an observational cohort study.
Ruigómez A; Kool-Houweling LMA; García Rodríguez LA; Penning-van Beest FJA; Herings RMC
Curr Med Res Opin; 2017 Dec; 33(12):2251-2259. PubMed ID: 28562108
[TBL] [Abstract][Full Text] [Related]
13. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
[TBL] [Abstract][Full Text] [Related]
14. A multicenter cohort analysis of fractures in histamine-2-receptor antagonist treated pediatric patients.
Fleishman NR; Richardson T; Attard TM
Curr Med Res Opin; 2022 Apr; 38(4):565-570. PubMed ID: 35112645
[TBL] [Abstract][Full Text] [Related]
15. Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists and Risk of Pneumonia in Patients with Acute Stroke.
Momosaki R; Yasunaga H; Matsui H; Fushimi K; Abo M
J Stroke Cerebrovasc Dis; 2016 May; 25(5):1035-1040. PubMed ID: 26853142
[TBL] [Abstract][Full Text] [Related]
16. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit.
MacLaren R; Reynolds PM; Allen RR
JAMA Intern Med; 2014 Apr; 174(4):564-74. PubMed ID: 24535015
[TBL] [Abstract][Full Text] [Related]
17. Renal Transplant Acute Rejection with Lower Mycophenolate Mofetil Dosing and Proton Pump Inhibitors or Histamine-2 Receptor Antagonists.
Patel KS; Stephany BR; Barnes JF; Bauer SR; Spinner ML
Pharmacotherapy; 2017 Dec; 37(12):1507-1515. PubMed ID: 28976570
[TBL] [Abstract][Full Text] [Related]
18. Effects of daily treatment with acid suppressants for stress ulcer prophylaxis on risk of ventilator-associated events.
Li X; Klompas M; Menchaca JT; Young JG
Infect Control Hosp Epidemiol; 2020 Feb; 41(2):187-193. PubMed ID: 31818336
[TBL] [Abstract][Full Text] [Related]
19. Proton pump inhibitors and histamine-2 receptor antagonists on the risk of pancreatic cancer: a systematic review and meta-analysis.
Laoveeravat P; Thavaraputta S; Vutthikraivit W; Suchartlikitwong S; Mingbunjerdsuk T; Motes A; Nugent K; Rakvit A; Islam E; Islam S
QJM; 2020 Feb; 113(2):100-107. PubMed ID: 31503318
[TBL] [Abstract][Full Text] [Related]
20. Maintenance Proton Pump Inhibitor Use Associated with Increased All-Cause and Cause-Specific Mortality in Sweden.
Ngwenya S; Simin J; Brusselaers N
Dig Dis Sci; 2023 Jun; 68(6):2252-2263. PubMed ID: 36629968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
